In Living Cell Technologies’s (LCT) first Phase I/IIa trial of DiabeCell, its lead product of encapsulated porcine insulin producing cells, five patients have been implanted with the lowest dose.
As reported in the company’s clinical update on March 31, 2008, there have been no significant adverse effects and a clinical effect was demonstrated with reduction in daily insulin requirement for up to six months follow up with satisfactory control of blood glucose.
Bob Elliott, medical director of LCT, said: “The clinical effects observed with the lowest dose and the uncomplicated safety profile to date have encouraged our clinical experts in Moscow to implant higher doses with the expectation of greater clinical benefit.”